Affordable Access

deepdyve-link
Publisher Website

MicroRNAs as mediators of drug resistance mechanisms.

Authors
  • Lampis, Andrea1
  • Hahne, Jens C2
  • Hedayat, Somaieh2
  • Valeri, Nicola3
  • 1 Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. Electronic address: [email protected]
  • 2 Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • 3 Division of Molecular Pathology and Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; Department of Medicine, The Royal Marsden Hospital, London and Sutton, UK.
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Sep 05, 2020
Volume
54
Pages
44–50
Identifiers
DOI: 10.1016/j.coph.2020.08.004
PMID: 32898724
Source
Medline
Language
English
License
Unknown

Abstract

MicroRNAs are small RNA transcripts involved in fine-tuning of several cellular mechanisms and pathways crucial for maintaining cells' homeostasis like apoptosis, differentiation, inflammation and cell-cycle regulation. They act by regulation of gene expression at post-transcriptional level through fine-tuning of target proteins expression. Expression of microRNAs is cell-type specific and since their discovery they have been proven to be deregulated in various disorders including cancer. Several lines of evidence are emerging that link microRNAs to drug resistance mechanisms in tumours given their important role in modulating oncogenic and tumour suppressive mechanisms. This review will focus on latest knowledge of the roles and mechanisms of microRNAs as mediators to drug resistance and the implications for future therapies. Copyright © 2020 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times